Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Mirae Asset Global Investments Co. Ltd. lowered its position in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 57.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,794 shares of the company’s stock after selling 59,588 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.15% of Fulgent Genetics worth $1,266,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Asset Management One Co. Ltd. lifted its position in Fulgent Genetics by 60.8% during the fourth quarter. Asset Management One Co. Ltd. now owns 2,039 shares of the company’s stock valued at $61,000 after purchasing an additional 771 shares during the period. Teza Capital Management LLC purchased a new stake in shares of Fulgent Genetics during the third quarter worth about $200,000. Nomura Holdings Inc. bought a new stake in shares of Fulgent Genetics during the third quarter valued at approximately $548,000. Mutual Advisors LLC lifted its stake in Fulgent Genetics by 5.2% in the 3rd quarter. Mutual Advisors LLC now owns 9,370 shares of the company’s stock worth $251,000 after purchasing an additional 462 shares in the last quarter. Finally, Covestor Ltd lifted its position in shares of Fulgent Genetics by 48.0% in the third quarter. Covestor Ltd now owns 1,508 shares of the company’s stock worth $40,000 after buying an additional 489 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

NASDAQ FLGT opened at $20.56 on Tuesday. Fulgent Genetics, Inc. has a fifty-two week low of $19.88 and a fifty-two week high of $44.09. The stock has a 50-day simple moving average of $22.55 and a two-hundred day simple moving average of $25.29. The firm has a market capitalization of $614.74 million, a P/E ratio of -3.65 and a beta of 1.43.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Wednesday, February 28th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.61. Fulgent Genetics had a negative net margin of 58.03% and a negative return on equity of 3.04%. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $67.14 million. As a group, analysts forecast that Fulgent Genetics, Inc. will post -2.04 earnings per share for the current year.

Analyst Ratings Changes

Separately, Piper Sandler dropped their target price on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Wednesday, March 6th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.